1.	Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Under 3 Sponsor: NCI, Other Protocol IDs: CDR0000483683, COG-ACNS0334, ACNS0334, NCT00336024
2.	Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 3 to 21 Sponsor: NCI, Other Protocol IDs: CDR0000511991, COG-ACNS0332, ACNS0332, NCT00392327
3.	Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor Phase: Phase III Type: Treatment Status: Active Age: 3 to 21 at diagnosis Sponsor: Other Protocol IDs: SJMB03, SJCRH-SJMB03, NCT00085202
4.	Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 50 and under Sponsor: NCI, Other Protocol IDs: CDR0000687639, COG-AEWS1031, AEWS1031, NCT01231906
5.	A Phase I/II Study of the Photon Radiosurgery System Phase: Phase II, Phase I Type: Treatment Status: Active Age: 2 to 32 Sponsor: Pharmaceutical / Industry Protocol IDs: CNS 0201, NCT00179907
6.	Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 1 to 21 Sponsor: NCI, Other Protocol IDs: CDR0000647587, COG-ADVL0912, ADVL0912, NCT00939770
7.	Melphalan, Carboplatin, and Sodium Thiosulfate for Patients With Central Nervous System (CNS) Embryonal or Germ Cell Tumors Phase: Phase II, Phase I Type: Treatment Status: Active Age: 1 to 30 Sponsor: Other Protocol IDs: OHSU-5056, SOL-08131-L, NCT00983398
8.	To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 2 to 20 Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: 100220, IND 59,056, NCT01222780
9.	Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 4 to 21 Sponsor: Other Protocol IDs: 10-096, NCT01294670
10.	Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor (PNET) Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 21 and under Sponsor: Other Protocol IDs: Pro00018020, NCT01326104
11.	High Risk Primitive Neuroectodermal (PNET) Brain Tumors in Childhood Phase: Phase II Type: Treatment Status: Active Age: 10 and under Sponsor: Other Protocol IDs: PNET HR, NCT00180791
12.	Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Any age Sponsor: Other Protocol IDs: 05-122, MSKCC-05122, NCT00445965
13.	High-dose Chemotherapy With Autologous Stem Cell Rescue in Pediatric High-risk Brain Tumors Phase: Phase II Type: Treatment Status: Active Age: Children Sponsor: Other Protocol IDs: 2005-12-009, NCT00798811
14.	Studies of Temozolomide in Combination With Topotecan in Refractory and Relapsed Paediatric Solid Tumours Phase: Phase II Type: Treatment Status: Active Age: 6 months to 20 years Sponsor: Other Protocol IDs: CSET 2008/1378, NCT00918320
15.	Treatment of High-Risk Cerebral Primitive Neuroectodermal Tumors in Children Aged Over 5 Years Phase: Phase II Type: Treatment Status: Active Age: 5 to 19 Sponsor: Other Protocol IDs: PNET HR+ 5, CSET 1329, NCT00936156
16.	Antineoplaston Therapy in Treating Children With Brain Tumors Phase: Phase II Type: Treatment Status: Active Age: 6 months to 17 years Sponsor: Other Protocol IDs: CDR0000066490, BC-BT-10, NCT00003458
17.	Antineoplaston Therapy in Treating Children With Primary Malignant Brain Tumors Phase: Phase II Type: Treatment Status: Active Age: 6 months to 17 years Sponsor: Other Protocol IDs: CDR0000066513, BC-BT-22, NCT00003476
18.	Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors Phase: Phase II Type: Treatment Status: Active Age: 21 and under Sponsor: NCI Protocol IDs: NCI-2011-02605, ACNS0821, U10CA098543, COG-ACNS0821, NCT01217437
19.	Tandem High Dose Chemotherapy and Autologous Stem Cell Rescue for High Risk Pediatric Brain Tumors Phase: Phase II Type: Treatment Status: Active Age: 21 and under Sponsor: Other Protocol IDs: SNUCH-SCT-1102, NCT01342237
20.	A Study of Avastin (Bevacizumab) in Combination With Temolozomide (TMZ) and Radiotherapy in Paediatric and Adolescent Patients With High-Grade Glioma Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 3 to 18 Sponsor: Pharmaceutical / Industry Protocol IDs: BO25041, 2010-022189-28, ITCC-019, HGG-01, NCT01390948
21.	Irinotecan Combination Chemotherapy for Refractory or Relapsed Brain Tumor in Children and Adolescents Phase: Phase II Type: Treatment Status: Active Age: 19 and under Sponsor: Other Protocol IDs: SNUCH-1201, NCT01535183
22.	Concurrent Carboplatin and Reduced Dose Craniospinal Radiation for Medulloblastoma and Primitive Neuroectodermal Tumor (PNET) Phase: Phase II Type: Treatment Status: Active Age: 3 to 25 Sponsor: Other Protocol IDs: 06-1151, NCT01542736
23.	Irinotecan in Combination With Cisplatin in Pediatric Patients With Unfavorable Prognosis Gliomas Phase: Phase II Type: Treatment Status: Active Age: 6 to 18 Sponsor: Other Protocol IDs: HSJD-GLIOMAS-IC, NCT01574092
24.	Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors Phase: Phase II Type: Treatment Status: Active Age: 12 to 21 Sponsor: NCI, Other Protocol IDs: PBTC-036, NCI-2013-00482, U01CA081457, NCT01836549
25.	Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain Tumors. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase I Type: Treatment Status: Active Age: 3 to 70 Sponsor: Other Protocol IDs: MCW-7594, MCW-CHW-511, MCW-CHW-9411, NCI-V95-0652, NCT00002647